Category Specific RSS

Categories: News

ResApp’s sleep apnoea app now available on Apple App Store

Australians that are struggling to get a good night sleep can now screen their likelihood of suffering from sleep apnoea with medtech company ResApp Health (ASX: RAP) having launched their clinically tested SleepCheck app on the iPhone App Store. 

By downloading the smartphone app, SleepCheck can record and analyse breaking and snorting sounds during sleep to provide an assessment of the likelihood the user suffers from sleep apnoea. 

“We are excited to announce that SleepCheck is now available on the App Store. For the first-time, consumers have direct access to a clinical-grade, regulatory-approved screening tool for sleep apnoea,” said Resapp Managing Director, Tony Keating.

“Over a third of Australian adults do not get the duration or quality of sleep needed, which has major consequences for their health, safety and quality of life. 

“Many adults snore, and loud snoring is an important indicator of sleep apnoea, although it often is ignored. SleepCheck offers an easy way to check if there’s more to your snore.”

Clinically tested through a 308 patient study, the SleepCheck algorithms provided an accurate assessment to identify obstructive sleep apnoea when compared to a simultaneous at-home comprehensive sleep study. With the trials validated, the software was approved in Europe to be CE Marked and in Australia by the Therapeutic Goods Association. 

iPhone users can download the SleepCheck app for $7.99 (£4.99 in the UK) while ResApp expects it to make it available on Android devices later in the year. 

Once the app collects sufficient data, users are provided with a low, medium, high or very high rating to classify their risk of having sleep apnoea and provided with recommended next steps. 

Alongside SleepCheck, ResApp has another smartphone app for the diagnosis and management of respiratory diseases. To develop the project further, the Company has partnered with global health products manufacturer RB to build and test a prototype.

 

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US

Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with…

1 week ago

June 2025 quarter CPI no roadblock to August RBA rate cut

The June 2025 quarter CPI data released today were cheered by mortgage holders and share…

2 weeks ago

Vection Secures $7.3M Defence Extension as AI Demand Strengthens

AI Gains Ground in Defence Sector As governments increase investment in defence technology, AI-powered tools…

2 weeks ago

Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology

Calix Limited (ASX:CXL) has taken a significant leap forward in developing Australia’s low-emissions steel value…

3 weeks ago

Harris Technology boosts retail margins in FY25 through growth of refurbished tech

Online tech retailer Harris Technology (ASX: HT8) has delivered a strong lift in gross product…

3 weeks ago

Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.

In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics…

4 weeks ago